The normal functions of peptides that aggregate in Alzheimer’s, Parkinson’s, and Huntington’s have been largely overlooked by scientists, but some argue that they are critical for understanding the development of disease.

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

Research identifies 10 types of dopamine-making neurons, one of which seems to die off during the disease.

The Swiss Federal Institute of Technology Lausanne evolutionary neurobiologist is using Drosophila to investigate how organisms adapt to novel environments.

His work was pivotal to understanding the mechanisms of neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s.

Making specific alterations to the bacterial population in a rat’s lungs either better protects the animals against multiple sclerosis–like symptoms or makes them more vulnerable, a study finds—the first demonstration of a lung-brain axis.

Conservation of structures and functions between single-celled fungi and human cells allow researchers to probe the brain.

Meet some of the people featured in the October 2021 issue of The Scientist.

The single-celled fungus allows researchers to study Alzheimer’s, Parkinson’s, ALS and other brain diseases with unparalleled speed and scale.

The cell conversion strategy restores neurons and motor functions lost as a result of an induced Parkinson’s-like illness in the animals.

The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.

The BioCollective, a company that transforms whole stool samples into microbial metadata, is developing the US’s first national microbiome reference material.

The plant geneticist has revolutionized researchers’ understanding of how light affects plant growth and development, and is engineering plants to combat climate change.